Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527539 | 1.00 | PPARD (0.47) | PPARDTSHRCYP3A4TP53TDP1 | |
| SCHEMBL4881306 | 0.89 | PPARD (0.56) | PPARDTSHRCYP3A4TP53TDP1 | |
| SCHEMBL4882046 | 0.89 | PPARD (0.56) | PPARDTSHRCYP3A4TP53TDP1 | |
| SCHEMBL23430674 | 0.85 | PPARD (0.52) | PPARDTSHRCYP3A4TP53TDP1 | |
| SCHEMBL3220479 | 0.83 | PPARD (0.50) | PPARDTSHRCYP3A4TP53TDP1 | |
| SCHEMBL14007050 | 0.82 | PPARD (0.48) | PPARDTSHRCYP3A4TP53TDP1 | |
| SCHEMBL23786286 | 0.81 | PPARD (0.52) | PPARDTSHRCYP3A4TP53TDP1 | |
| SCHEMBL4164665 | 0.81 | PPARD (0.56) | PPARDTSHRTP53TDP1ALDH1A1 | |
| SCHEMBL23962601 | 0.80 | PPARD (0.47) | PPARDTSHRCYP3A4TP53TDP1 | |
| SCHEMBL20990630 | 0.80 | PPARD (0.63) | PPARDTSHRCYP3A4TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10098949-B2 | Adsorption of immunopotentiators to insoluble metal salts | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2018-10-16 | — | — | US | disclosed |
| US-9950062-B2 | Compounds and compositions as TLR activity modulators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-04-24 | — | — | US | disclosed |
| EP-2473508-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| EP-2822947-B1 | ARGININE SALTS OF A TLR7 AGONIST | GLAXOSMITHKLINE BIOLOG SA (BE) | 2016-08-03 | — | — | EP | disclosed |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-07-28 | — | — | US | disclosed |
| US-9365506-B2 | Compounds and compositions as TLR2 agonists | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-9320748-B2 | Immunologically useful arginine salts | NOVARTIS AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9320748-B2 | Immunologically useful arginine salts | NOVARTIS AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9315530-B2 | Adsorption of immunopotentiators to insoluble metal salts | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20120237546-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-2480253-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | Novartis AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120177681-A1 | Formulation of immunopotentiators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-07-12 | — | — | US | disclosed |
| EP-2473508-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2012-07-11 | — | — | EP | disclosed |
| EP-2459216-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| WO-2012031140-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011119759-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011049677-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011027222-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | PPARD 256/4885TSHR 3415/4885CYP3A4 4745/4885 |
| US-20120237546-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | PPARD 256/4885TSHR 3415/4885CYP3A4 4745/4885 |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | PPARD 256/4885TSHR 3415/4885CYP3A4 4745/4885 |
| US-10098949-B2 | Adsorption of immunopotentiators to insoluble metal salts | CD69, NFATC1, CD209 | PPARD 3084/4885TSHR 3311/4885CYP3A4 3090/4885 |
| US-20120177681-A1 | Formulation of immunopotentiators | CD69, CD4, ICOS | PPARD 2623/4885TSHR 2960/4885CYP3A4 2345/4885 |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | PPARD 2900/4885TSHR 3024/4885CYP3A4 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.